Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study

Annals of the Rheumatic Diseases

Volumn 65, Issue 6, 2006, Pages 753-759

  Weinblatt, M E ^a   Keystone, E C ^b   Furst, D E ^c   Kavanaugh, A F ^d   Chartash, E K ^e   Segurado, O G ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; METHOTREXATE; PLACEBO; PREDNISONE;

ADULT; AGED; ARTICLE; BACTERIAL ARTHRITIS; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DEMYELINATING DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG LABELING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HISTOPLASMOSIS; HUMAN; LONG TERM CARE; LYMPHOMA; MAJOR CLINICAL STUDY; PANCYTOPENIA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; TIME FACTORS;

EID: 33744479185     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.044404     Document Type: Article

References (35)

1. Choy E, Panayi G. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
2. Lee D, Weinblatt M. Rheumatoid arthritis. Lancet 2001;358:903-11.
3. O'Dell J. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
4. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonists (IL-1 ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005;64(suppl IV):iv2-14.
5. Weinblatt M, Keystone E, Furst D, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
6. Furst D, Schiff M, Fleischmann R, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully anti-tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) J Rheumatol 2003;30:2563-71.
7. van de Putte I, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16.
8. Keystone E, Kavanaugh A, Sharp J, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimimab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum 2004;50:1400-11.
9. Lipsky P, van der Heijde D, St Clair E, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy group. N Engl J Med 2000;343:1594-602.
10. Maini R, Breeveld F, Kalden J, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
11. St Clair E, Desiree M, van der Heijde D, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum 2004;50:3432-43.
12. Klareskog L, van der Heijde D, de Jager J, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
13. Genovese M, Bathon J, Martin R, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
14. Weinblatt M, Kremer J, Bankhurst A, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
15. Kremer J, Weinblatt M, Bankhurst A, Bulpitt KJ, Fleischmann RM, Jackson CG, et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis. Continued observations. Arthritis Rheum 2003;6:1493-9.
16. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.
17. Arnett F, Edworthy S, Bloch D, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
18. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
19. Prevoo M, van 'T Hof M, Kuper H, van Leeuwent, M, van de Putte L, Riel P. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 1995;38:44-8.
20. Prevoo M, van Gestel A, van 'T Hof M, van Rijswijk M, van de Putte L, van Riel P. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996;35:1101-5.
21. Lubeck D. Health-related quality of life measurements and studies in rheumatoid arthritis. Am J Manag Care 2002;8:811-20.
22. Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-1999), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission.
23. Balsa A, Carmona L, Gonzalez-Alvaro I, Belmonte MA, Tena X, Sanmarti R. Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol 2004;31:40-6.
24. Goldsmith CH, Boers M, Bombardier C, Tugwell P. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol 1993;20:561-5.
25. Weinblatt M. Rheumatoid arthritis in 2003: where are we now with treatment? Ann Rheum Dis 2003;62(suppl 2):ii94-6.
26. Wolfe F, Rehman Q, Lane N, Kremer J. Starting a disease modifying antirheumatic drug or a biologic agent in rheumatoid arthritis: standards of practice for RA treatment. J Rheumatol 2001;28:1704-11.
27. Lambert C, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate. A randomized, controlled trial. Arthritis Rheum 2004;50:364-71.
28. O'Dell J, Haire C, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalzine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
29. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER Study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2005;54:26-37.
30. Breedveld F, Han C, Bala M, van der Heijde D, Baker D, Kavanaugh AF, et al. Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:52-5.
31. Scott D, Punger K, Kaarela K, Doyle DV, Woolf A, Holmes J, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000;39:122-32.
32. Flendrie M, Creemers M, Welsing J, den Broeder A, van Riel P. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003;62(suppl II):ii30-3.
33. Doran M, Crowson C, Pond G, O'Fallon W, Gabriel S. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2003;46:2294-300.
34. Doran M, Crowson C, Pond G, O'Fallon W, Gabriel S. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
35. Geborek P, Bladström A, Turesson C, Gulfe A, Petersson I, Saxne T, et al. TNF blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703.